Mr. Serge Verreault reports

CRESCITA EXPANDS MEDICAL AESTHETIC PORTFOLIO WITH MICRONJETTM600 THE WORLD'S SMALLEST INTRADERMAL DELIVERY DEVICE

Crescita Therapeutics Inc. has signed an exclusive distribution agreement with NanoPass Technologies Ltd., a pioneer in the development and commercialization of an advanced intradermal delivery device, to launch and distribute MicronJet600 in the Canadian medical aesthetics market.

MicronJet is an innovative intradermal injection device, leveraging the proven MEMS technology, that offers a highly effective, consistent and virtually pain-free delivery of aesthetic products and therapeutic substances. With three 0.6-millimetre, silicon crystal-made delivery pyramids, MicronJet can be attached to standard syringes and will provide aesthetic clinicians with the least invasive and most precise intradermal delivery on the market today, allowing administration to delicate and sensitive areas such as around the eyes, neck and decollete area, as well as to the full face, for optimal patient outcomes.

"MicronJet is a great addition to our medical aesthetic portfolio, enhancing our offerings alongside NCTF135 HA, Art Filler and Pliaglis. This novel device provides precision in penetration depth, no bruising and comfortable injection, all of which are welcomed by medical practitioners and patients alike," stated Serge Verreault, president and chief executive officer of Crescita. "Bringing innovative products to Canadian practitioners and patients aligns with our strategic vision to establish ourselves as a leading player in our market," added Mr. Verreault.

Crescita will be responsible for obtaining regulatory approval for MicronJet from Health Canada and plans to launch the product promptly thereafter, which is currently anticipated to be in the first half of 2025. MicronJet has been accepted by patients worldwide and is supported by over 70 clinical studies and multiple peer-reviewed publications. MicronJet is CE marked, United States FDA (Food and Drug Administration) cleared, ISO 13485 certified and is currently approved in Australia and several other jurisdictions in Europe, Asia and the Middle East.

Daniel Levitats, CEO of NanoPass, added: "We're thrilled to collaborate with Crescita to bring advanced delivery solutions to the Canadian market and support more clinicians in expanding their practice, delivering improved patient outcomes and increasing treatment satisfaction. This collaboration marks an exciting step in NanoPass's commercial growth goals towards becoming the new intradermal delivery standard."

About Crescita Therapeutics Inc.

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D (research and development) and manufacturing capabilities.

We seek Safe Harbor.